<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33785574</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impact of a frequent nearsplice <i>SOD1</i> variant in amyotrophic lateral sclerosis: optimising <i>SOD1</i> genetic screening for gene therapy opportunities.</ArticleTitle><Pagination><StartPage>942</StartPage><EndPage>949</EndPage><MedlinePgn>942-949</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-325921</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mutations in superoxide dismutase 1 gene (<i>SOD1)</i>, encoding copper/zinc superoxide dismutase protein, are the second most frequent high penetrant genetic cause for amyotrophic lateral sclerosis (ALS) motor neuron disease in populations of European descent. More than 200 missense variants are reported along the SOD1 protein. To limit the production of these aberrant and deleterious SOD1 species, antisense oligonucleotide approaches have recently emerged and showed promising effects in clinical trials. To offer the possibility to any patient with SOD1-ALS to benefit of such a gene therapy, it is necessary to ascertain whether any variant of unknown significance (VUS), detected for example in <i>SOD1</i> non-coding sequences, is pathogenic.</AbstractText><AbstractText Label="METHODS">We analysed SOD1 mutation distribution after SOD1 sequencing in a large cohort of 470 French familial ALS (fALS) index cases.</AbstractText><AbstractText Label="RESULTS">We identified a total of 27 SOD1 variants in 38 families including two SOD1 variants located in nearsplice or intronic regions of the gene. The pathogenicity of the c.358-10T&gt;G nearsplice <i>SOD1</i> variant was corroborated based on its high frequency (as the second most frequent SOD1 variant) in French fALS, the segregation analysis confirmed in eight affected members of a large pedigree, the typical SOD1-related phenotype observed (with lower limb onset and prominent lower motor neuron involvement), and findings on postmortem tissues showing SOD1 misaccumulation.</AbstractText><AbstractText Label="CONCLUSIONS">Our results highlighted nearsplice/intronic mutations in <i>SOD1</i> are responsible for a significant portion of French fALS and suggested the systematic analysis of the <i>SOD1</i> mRNA sequence could become the method of choice for <i>SOD1</i> screening, not to miss these specific cases.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muratet</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teyssou</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiot</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boill&#xe9;e</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5518-9005</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobsiger</LastName><ForeName>Christian S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohl</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gyorgy</LastName><ForeName>Beata</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5543-7208</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guegan</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amador</LastName><ForeName>Maria Del Mar</ForeName><Initials>MDM</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AP-HP, D&#xe9;partement de Neurologie, Centre de r&#xe9;f&#xe9;rence SLA Ile de France, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AP-HP, D&#xe9;partement de Neurologie, Centre de r&#xe9;f&#xe9;rence SLA Ile de France, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>H&#xf4;pital des Peupliers, Ramsay General Health Group, Paris, &#xce;le-de-France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, H&#xf4;pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Universit&#xe9; de Lyon, Bron, Auvergne-Rh&#xf4;ne-Alpes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut NeuroMyoG&#xe8;ne, CNRS UMR5310, INSERM U1217, Facult&#xe9; de M&#xe9;decine Rockefeller, Universit&#xe9; Claude Bernard Lyon I, Lyon, Auvergne-Rh&#xf4;ne-Alpes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoine</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Centre de Ressource et de Comp&#xe9;tence SLA, H&#xf4;pital Nord, CHU de Saint-Etienne, Saint-Etienne, Rh&#xf4;ne-Alpes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camdessanch&#xe9;</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-5282-6707</Identifier><AffiliationInfo><Affiliation>Service de Neurologie, Centre de Ressource et de Comp&#xe9;tence SLA, H&#xf4;pital Nord, CHU de Saint-Etienne, Saint-Etienne, Rh&#xf4;ne-Alpes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1287-7355</Identifier><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, H&#xf4;pital Gui de Chauliac, CHU de Montpellier, Universit&#xe9; de Montpellier, Montpellier, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazeneuve</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de G&#xe9;n&#xe9;tique et Cytog&#xe9;n&#xe9;tique, Unit&#xe9; Fonctionnelle de neurog&#xe9;n&#xe9;tique mol&#xe9;culaire et cellulaire, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le-de-France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauret-Amsellem</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de G&#xe9;n&#xe9;tique et Cytog&#xe9;n&#xe9;tique, Unit&#xe9; Fonctionnelle de neurog&#xe9;n&#xe9;tique mol&#xe9;culaire et cellulaire, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le-de-France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leguern</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de G&#xe9;n&#xe9;tique et Cytog&#xe9;n&#xe9;tique, Unit&#xe9; Fonctionnelle de neurog&#xe9;n&#xe9;tique mol&#xe9;culaire et cellulaire, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le-de-France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouzat</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, N&#xee;mes, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, INSERM, Universit&#xe9; de Montpellier, Montpellier, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guissart</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, N&#xee;mes, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, INSERM, Universit&#xe9; de Montpellier, Montpellier, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbroso</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Moleculaire, CHU Nimes, N&#xee;mes, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Motoneuron Disease: Pathophysiology and Therapy, INM, INSERM, Universit&#xe9; de Montpellier, Montpellier, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence SLA, D&#xe9;partement de Neurologie, CHRU Tours, Tours, Centre-Val de Loire, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253, Universit&#xe9; de Tours, Inserm, Tours, Centre-Val de Loire, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, Universit&#xe9; de Tours, Inserm, Tours, Centre-Val de Loire, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Biochimie et Biologie Mol&#xe9;culaire, CHU Tours, Tours, Centre-Val de Loire, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grapperon</LastName><ForeName>Aude-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence pour les Maladies Neuromusculaire et la SLA, H&#xf4;pital de la Timone, Assistance Publique H&#xf4;pitaux de Marseille, CHU de Marseille, Marseille, Provence-Alpes-C&#xf4;te d'Azur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attarian</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence pour les Maladies Neuromusculaire et la SLA, H&#xf4;pital de la Timone, Assistance Publique H&#xf4;pitaux de Marseille, CHU de Marseille, Marseille, Provence-Alpes-C&#xf4;te d'Azur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschueren</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence pour les Maladies Neuromusculaire et la SLA, H&#xf4;pital de la Timone, Assistance Publique H&#xf4;pitaux de Marseille, CHU de Marseille, Marseille, Provence-Alpes-C&#xf4;te d'Azur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seilhean</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3498-4602</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Neuropathologie, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, &#xce;le-de-France, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millecamps</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0745-6735</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM,Inserm, CNRS, APHP, H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, &#xce;le de France, France stephanie.millecamps@upmc.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):914</RefSource><PMID Version="1">33906934</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="Y">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33785574</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-325921</ArticleId><ArticleId IdType="pii">jnnp-2020-325921</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>